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Abstract
Background: The number of total knee replacements (TKRs) and total hip replacements (THRs) has been increasing
noticeably in high-income countries, such as Germany. In particular, the number of revisions is expected to rise
because of higher life expectancy and procedures performed on younger patients, impacting the budgets of
health-care systems. Quality transparency is the basis of holistic patient pathway optimization. Nevertheless, a
nation-wide cross-sectoral assessment of quality from a patient perspective does not yet exist. Several studies have
shown that the use of patient-reported outcome measures (PROMs) is effective for measuring quality and
monitoring post-treatment recovery. For the first time in Germany, we test whether early detection of critical
recovery paths using PROMs after TKR/THR improves the quality of care in a cost-effective way and can be
recommended for implementation into standard care.
Methods/design: The study is a two-arm multi-center patient-level randomized controlled trial. Patients from nine
hospitals are included in the study. Patient-centered questionnaires are employed to regularly measure digitized
PROMs of TKR/THR patients from the time of hospital admission until 12 months post-discharge. An expert
consortium has defined PROM alert thresholds at 1, 3, and 6 months to signal critical recovery paths after TKR/THR.
An algorithm alerts study assistants if patients are not recovering in line with expected recovery paths. The study
assistants contact patients and their physicians to investigate and, if needed, adjust the post-treatment protocol.
When sickness funds’ claims data are added, the cost-effectiveness of the intervention can be analyzed.
Discussion: The study is expected to deliver an important contribution to test PROMs as an intervention tool and
examine the determinants of high-quality endoprosthetic care. Depending on a positive and cost-effective impact,
the goal is to transfer the study design into standard care. During the trial design phase, several insights have been
discovered, and there were opportunities for efficient digital monitoring limited by existing legacy care models.
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Digitalization in hospital processes and the implementation of digital tools still represent challenges for hospital
personnel and patients. Furthermore, data privacy regulations and the separation between the in- and outpatient
sector are roadblocks to effectively monitor and assess quality along the full patient pathway.
Trial registration: German Clinical Trials Register: DRKS00019916. Registered November 26, 2019 – retrospectively
registered.
Keywords: Health-care policy, PROM, Quality of care, TKR, THR, Value-based health care, Randomized controlled trial
Background
Total knee replacements (TKRs) and total hip replace-
ments (THRs) are among the most frequent and increasing
surgeries in high-income countries, such as Germany. They
are considered to be effective but also highly invasive pro-
cedures to treat osteoarthritis in the knee and hip. In 2016,
in Germany, there were more than 187,000 procedures
(230 per 100,000 population) for TKRs – a 38% increase
compared with 2006 – and 233,000 procedures (280 per
100,000 population) for THRs – a 17% increase compared
with 2006 [1–3]. Moreover, the number of primary as well
as revision procedures is expected to rise steadily because
of increased life expectancies and procedures performed
on younger patients [2]. This development has a significant
impact on the budgets of health-care systems. Measuring
patient-reported quality helps to generate transparency, to
evaluate treatments, and as a consequence to optimize pa-
tients’ pathways (indication, procedure, and recovery), lead-
ing to enlarged revision horizons and a decreased number
of revisions [4].
Quality of joint replacement in Germany is measured
and monitored by several mandatory or voluntary initia-
tives. They concentrate on the collection and analyses of
clinical quality indicators and administrative data as well as
the adherence to structural and processual standards and
the interpretation of medical documentation [5]. These
quality initiatives are limited mostly to the acute inpatient
sector [6]. A nation-wide standardized and cross-sectoral
assessment of quality from a patient perspective does not
exist yet. As a result, the improvement of arthroplasty-
relevant problems such as post-operative joint functional-
ity, pain, or constraints in daily life cannot be assessed by
the existing quality measurement tools. However, an im-
provement in those quality dimensions defines treatment
success [7] and significantly affects patient utility [8]. Con-
sequently, a recent study in the UK concluded that, for
patients with THR, quality measured by patient-reported
outcomes (PROMs) significantly affects patient utility in
the form of willingness to travel and hospital demand posi-
tively. In contrast, existing quality indicators such as mor-
tality rates or readmission rates have either only a small
positive or even insignificant effect [8].
Furthermore, increased transparency of the patients’ re-
covery process using PROMs initiates a direct feedback
mechanism between physician and patient, thus optimiz-
ing surgeries [9, 10] and best practice sharing [7]. At
present this is barely given. After rehabilitation, patients
will seldom return to the hospital for follow-up visits and
instead they see their family physicians or outpatient spe-
cialists. Unfortunately, communication channels between
hospitals and follow-up physicians are often not present,
preventing any feedback mechanism regarding their pa-
tients’ recovery process [11].
For example, the effects of improved medical quality
by continuously monitoring patients after surgery using
PROMs have been concluded in a study of patients with
cancer [12, 13]. The study shows that, during routine
treatment, constant monitoring and early detection of
critical recovery paths via PROMs significantly improved
survival rates and decreased the number of emergency
visits [12, 13].
Our study is designed to go beyond testing the effect-
iveness of PROMs as a quality measurement instrument.
For the first time in Germany, we want to test whether
an early detection of critical recovery paths after TKR/
THR via PROMs and change of post-treatment pathways
improves clinical quality indicators such as readmissions
and patient-centered quality measures such as health-
related quality of life and joint functionality and, in turn,
leads to a decrease of health-care costs. The study focuses
on two specific questions: (a) Can the use of PROMs after
TKR/THR impact the patient pathway in a positive and
cost-effective manner? (b) Can we recommend the imple-
mentation of PROMs into standard care, and what are
best practices to follow?
Methods/Design
Overall study design
This study is a two-arm multi-center patient-level ran-
domized controlled trial (RCT). Patient-centered ques-
tionnaires are employed digitally to regularly measure
PROMs of patients with TKR and THR from the time of
hospital admission until 12 months after discharge. With
the support of an expert consortium of physicians,
PROM threshold alert values at 1, 3, and 6 months have
been defined to signal critical recovery of patients after
TKR/THR. With the help of an algorithm, patients and
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post-treatment physicians are alerted to intervene in
case of critical PROM values.
By adding cross-sectoral insurance claims data (resource
consumption: drugs, physiotherapy, specialist visits, com-
plications, infections, and hospital stays) at the patient
level, the study examines the effect of PROM-based moni-
toring of patients up to 12months post-surgery on the
clinical as well as patient-reported outcomes and its cost-
effectiveness.
Ethics, consent, permissions, and funding
The study is funded by the Innovation Fund of the German
Federal Joint Committee (G-BA) in the stream “Care
models with comprehensive and measurable results and
process responsibility”. The funding period is set between
April 1, 2019 and March 31, 2023. The study will be con-
ducted in accordance with the Declaration of Helsinki. The
study was approved primarily by the Charité’s Ethic Com-
mittee, Berlin (EA4/169/19). The other responsible ethical
review committees of participating hospitals (Medical
Chamber Hamburg, Medical Chamber Schleswig-Holstein,
Hannover Medical School, Friedrich-Schiller University
Jena, and Medical Chamber Brandenburg) agreed with the
decision. The study is registered at the German Clinical
Trials Register (DRKS) under trial number DRKS00019916.
All potentially eligible participants will be approached to
offer their informed consent to participate in the study.
The current protocol is version 1, dated January 15, 2020.
Any changes in the study design will be communicated to
all project partners, including hospitals.
Study setting
The study started on October 1, 2019 and will last for two
years, whereas patient recruitment will end after one year,
on September 30, 2020. The second year will concentrate
on follow-ups and corresponding interventions. After two
years, the study will be evaluated by an independent and
impartial research institute (aQua Institute, Göttingen,
Germany). Study centers are the nine participating hospi-
tals. These hospitals are located around Germany (seven
different federal states) and are among Germany’s leading
endoprosthetic centers. Hospitals differ in their type, in-
cluding university hospitals, specialized endoprosthetic cen-
ters, full-service providers, and specialist outpatient clinics.
Based on historical hospital case volumes for elective
TKR/THR to estimate expected workload, up to two
study assistants are employed at each center – funded
by means of the Innovation Fund – to operationalize the
study design in each center. Before the start of the pro-
ject, these study assistants were trained thoroughly in
workshops to be in line with the specifications of the
study design. The study assistants are responsible for all
study-related activities during the patients’ hospital stay
and for follow-up as well as the initiation and
documentation of interventions and a complete final
documentation of the participant after 12 months.
The study assistants and patients use a software inter-
face provided by HRTBT Medical Solutions GmbH
(Berlin, Germany), a digital solutions provider for hospi-
tals, to document patient enrollment, key procedure as-
pects, and the patient-reported outcomes. Patients’ health
procedure and claims data along the care pathway are
accessed via the participating German sickness funds
BARMER and BKK, both of which are part of the social
health insurance scheme [14]. These insurance claims data
will be extracted for four years (2018–2021) for those pa-
tients insured in one of these funds and having consented
to study design and data sharing.
Sample size
The estimation of the study’s sample size is based on
historical case volumes (identified by procedure codes
OPS 5–820 and 5–822) of the nine study hospitals from
2018. Hence, we expect around 17,500 patients to be eli-
gible in the 12-month recruiting time frame. This figure
already excludes emergency patients and minors. Fur-
thermore, prior field studies by HRTBT Medical Solu-
tions GmbH suggest that around 15% of patients reject
participation and around 30% of the remainder will not
finalize all follow-up surveys despite reminders and ac-
tive follow-up efforts. Consequently, we expect to reach
a sample size of around 10,500 participants having com-
pleted all follow-ups. This number is not yet adjusted
for people without direct or indirect access to the inter-
net or other technical constraints, but increasing case
volumes compared with 2018 are expected to balance
this effect.
Furthermore, it is expected that insurance claims data
for patients insured in the two participating sickness
funds (about 2700 patients) can be obtained, resulting in
a sample size of 2700 for our primary endpoint. If we as-
sume a statistical difference in effect between the inter-
vention and control groups of 0.15 standard deviations,
an error probability of less than 5%, and a power of 80%,
a sample size of only around 1400 patients with insur-
ance claims data is required for analysis.
Eligibility criteria
Eligible for this study are all patients with primary elect-
ive TKR and THR above the age of 18 having a sched-
uled surgery or pre-surgery visit between October 2019
and September 2020. Exclusion criteria for participation
are emergencies (e.g., femoral fracture), patients with
American Society of Anesthesiologists classification 4–6
(4: a patient with a life-threatening disease, 5: a mori-
bund patient who is unlikely to survive without surgery,
6: a deceased patient with confirmed brain death or an
organ donor), and patients younger than 18 years.
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Additionally, for practical reasons, patients without dir-
ect or indirect access to an e-mail account are excluded
from the study. E-mail addresses from relatives are ac-
cepted. All patients who deny participation will not be
included in the study.
Informed consent
All patients with a primary elective TKR or THR will be
approached by their corresponding study assistants for a
patient briefing once they have been scheduled for surgery
in the corresponding hospital. Patients will be informed by
either the study assistant or the corresponding physicians
of the study and its benefits, risks, and design. Additionally,
they are handed a comprehensive study information docu-
ment. Before patients are included, they are required to sign
an informed consent form for their study participation
(Supplement 1). The informed consent allows us to contact
the patient via e-mail, post, and telephone and to process
and link the patient’s data from different sources during
and after the study.
Patients are asked to sign two additional consent
forms: (a) one for processing their hospital administra-
tive data and (b) one for processing their insurance data
in case the patient is contracted with one of the partici-
pating sickness funds. Both of these consent forms are
optional and are not required to participate in the study.
Patients will be free to withdraw from either one of the
three consents without stating a reason. If the patients
withdraw from the consent for participation, all their data
will be deleted. Patients are allowed to participate in other
studies as long as these do not interfere with our study.
Participant timeline
Each participant will be participating in the study for a
maximum of 12 months plus the duration of the hospital
stay, starting with the admission day followed by the in-
patient stay and the discharge and post-discharge period.
The participant will have to answer two questionnaires
during the hospital stay: at admission and discharge. At
discharge, the randomized allocation into the interven-
tion and control groups takes effect, and the participant
is followed up with electronic questionnaires either one
or four times in the 12months after hospital discharge.
With the final questionnaire after 12months, the study
will conclude for each participant regardless of allocation.
The timeline for the participants is presented in Fig. 1.
Baseline assessment
Baseline assessment takes place for all eligible partici-
pants at the day of admission into the hospital. The timing
differs slightly between the study centers. Three study cen-
ters perform the baseline assessment during their pre-
surgery examination days; this can be up to 6 weeks before
surgery. After giving informed consent, the participant will
be included in the study by providing name and e-
mail address. In the next step, while waiting for the
physician’s appointment, the participant is given a
tablet to respond to a 10- to 15-min questionnaire
consisting of basic demographic, comorbidity informa-
tion, and selected PROM sets.
The overall questionnaire is based on the ICHOM
(International Consortium for Health Outcomes Meas-
urement) Standard Set for Hip and Knee Osteoarthritis,
which consists of the EQ-5D-5L, HOOS-PS/KOOS-PS,
and an analogue pain scale. This set was refined by add-
ing the PROMIS Depression and Fatigue sets, as studies
show that the recovery process is also affected by pa-
tients’ mental conditions [15]. During selection of the
PROM sets, three criteria were of utmost importance.
First, the questionnaire should be brief to include it in
the hospital’s daily activities. Second, the sets should be
renowned and proven by literature. Finally, the com-
bined set of PROMs should cover all important patient-
related aspects of the osteoarthritic condition and the
elective TKR and THR procedures: health-related quality
of life, functionality, pain, and mental condition.
At discharge from the hospital, the participant once
again is handed a tablet to complete – alone or with the
help of the study assistant – a mostly identical question-
naire (omitting demographic and comorbidity questions).
Besides documenting the data from the questionnaire, the
study assistant will document additional parameters at
admission, after surgery, and at discharge, encapsulating
information on the participant’s medical history, the sur-
gery, and aftercare. In Fig. 1, the standard protocol items at
different points in time are shown.
Randomization and blinding
The allocation of participants occurs after completion of
the patient survey at the day of discharge; thus, during
inpatient stay, all eligible patients are treated equally. All
participants are stratified into patients with TKR or
THR and then randomly allocated at a ratio of 1:1 into
the intervention or control group. No further stratifica-
tions or corrections are performed. Owing to data
security regulations, randomization will be carried out
for each hospital individually. Figure 2 shows the
randomization flow. The study’s software provider will
be responsible for the randomization algorithm, and al-
location will be shown to the study assistant or the phys-
ician only after discharge of the participant. Hence,
during the inpatient stay, the hospital staff and the par-
ticipants are blinded. The participants will stay blinded
until the end of the study, not knowing whether they are
in the intervention or control group. Frequency of the
surveys is not disclosed to patients, in either the inter-
vention or control group.
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Intervention
Whereas participants in the control group will be asked
to complete only a final follow-up questionnaire 12
months post-discharge, participants in the intervention
group have to complete four follow-up questionnaires:
at months 1, 3, and 6 and a final follow-up 12months
after discharge. All follow-up questionnaires are sent via
e-mail and are answered electronically by the partici-
pants on their computers, smartphones, or tablets. In
case the participants do not have an e-mail account, e-
Fig. 1 Standard protocol items – PROMoting Quality
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mails are sent to relatives if agreed upon and jointly
filled out by relative and patient. Results from the ques-
tionnaires will be automatically transferred to the study’s
software and are observable by the hospitals’ study assis-
tants and physicians; 1-, 3-, and 6-month PROM set
scores will then be screened for critical values or un-
favorable developments.
When critical values or developments are detected, the
software alerts the study assistants of the corresponding
hospitals and an intervention is initiated. Interventions
are characterized by three steps. First, the study assistant
sends a standardized report to the participant, via post
or e-mail, where critical values and developments are
highlighted and a follow-up call is announced. Second,
the study assistant calls the participants by phone to in-
form them of the critical values, asking permission to
forward the PROM results to their outpatient specialist
or general practitioner and recommending a visit to their
physician to potentially adjust the treatment. Finally, a re-
port with the participant’s results will be forwarded, by
post or fax, to the outpatient physician. In the next regular
questionnaire, participants are asked to report changes in
their treatment schedule in order to document modifica-
tions in the outpatient physicians’ treatment with respect
to physiotherapy, medication, or surgery.
For health-related quality of life (EQ-5D-5L) and func-
tionality (KOOS-PS and HOOS-PS), critical absolute
values and unfavorable development in the recovery paths
were defined by an expert consortium of 13 orthopedic
physicians, representing all nine participating hospitals.
For this definition, the standard Delphi technique was
deployed. The advantage of the standard Delphi technique
is that it offers a structured process of collecting expert
opinions, approaching consensus, without being biased by
the domination effect of a few experts in open discussions
[16]. The physicians separately populated templates for
each item of the PROM sets – EQ-5D-5L (for hip and
knee) and KOOS-PS/HOOS-PS at 1, 3, 6, and 12months
after surgery – subject to answering the following ques-
tion: “Which patient value of this particular item would be
considered critical at 1, 3, 6, or 12 months after surgery to
schedule an appointment for a follow-up examination?”
Results were collected in one-on-one interviews, con-
solidated, and analyzed, and basic statistics were played
back to the physicians, offering them the chance to ad-
just their values. Feedback was collected and once again
consolidated, and results were played back and discussed
in a final joint call. Moreover, it was agreed that neither
the EQ-5D-5L nor KOOS-PS/HOOS-PS scores should
worsen over time. Defined values have additionally been
sanity-checked on historic values of patients of two par-
ticipating study centers in order to test their sensitivity.
For the PROMIS Fatigue and Depression scores, only
absolute critical values were set on the basis of existing
research; for example, a critical PROMIS Depression score
was set to the PHQ-9 (Patient Health Questionnaire-9)
classification of “moderately severe” depression [17]. All
critical values are summarized in Table 1.
Data quality enhancement
Each study assistant is provided with a digital dashboard
showing open tasks, critical value alerts, and patients’
Fig. 2 Randomization process
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activity related to receiving and answering follow-up
questionnaires. Each task is associated with a deadline,
and a color code reminds the study assistant of open
tasks. For the purpose of data completeness, the partici-
pants will be reminded by the software to fill in their
follow-up questionnaires 1, 2, and 7 days after the initial
follow-up questionnaires are sent out. If a participant
has not completed the questionnaire after three re-
minders, the study assistant will call to support him or
her.
Moreover, predefined standardized e-mails, guidelines for
the follow-ups, and intervention calls ensure consistency
between study centers. Furthermore, adherence to the
protocol given in the study design was promoted in training
on the ground and during a central workshop for all study
assistants and physicians.
Hospital administrative data, clinical quality data, and
insurance claims data
After completion of the last participant’s questionnaire
and only for those who have given consent, hospital ad-
ministrative data and insurance claims data will be added
to the participants’ PROM data. Hospital administrative
data are provided by the hospitals’ controlling department
on the basis of the hospital internal case number of the
patient. Insurance claims data are provided for partici-
pants who are insured at one of the participating sickness
funds and have given consent.
Outcomes
The overall aim of the study is to test the cost-
effectiveness of PROMs for early identification and there-
fore timely treatment of post-surgical complications or
the health-related quality decreasing developments or
both. The primary endpoint of the study is to investigate
cost-effectiveness and thus the optimization of outcome
quality compared with the resource utilization of the de-
signed intervention across the pathway. Outcome quality
is defined as a composite measure of PROMs and clinical
outcome measures such as re-operations. Utilized
resources are direct and indirect follow-up health-care
cost and the cost of implementing the designed
intervention.
Secondary outcomes include the improvement of the pa-
tients’ functionality reflected by the KOOS-PS/HOOS-PS;
of medium- to long-term health-related quality of life eval-
uated by the EQ-5D-5L; of pain in knee, hip, and lower
back; of satisfaction with treatment outcome (measured
through selected questions from the Patient Experience
Questionnaire, or PEQ); and of clinical outcome measures
such as post-operative revision and re-operation rates. Fur-
thermore, these analyses will be repeated with subgroups.
Specific analyses will be carried out to estimate the impact
of enhanced recovery programs or the choice of a specific
implant on patient-reported outcome quality, for example.
Statistical analysis
Data will be provided in electronic formats. A statistical
analysis program will be used to run tests and analyses.
For the planned statistical analyses, it has to be distin-
guished between the primary and the secondary outcome.
For primary outcome – the cost-effectiveness of using
PROMs in TKR/THR – a cost-effectiveness analysis
(CEA) will be conducted. In the CEA, alternatives will
be evaluated by costs and consequences (quality im-
provement) and mapped on a cost-effectiveness plane
[18] and thus create support for later policy recommen-
dations. For costs, the cross-sectoral sickness funds’
claims data on the patient level for direct and indirect
follow-up costs as well as the cost of the intervention
are taken into account to calculate incremental cost. For
the patients’ overall health status, a composite measure
is used. Results for each patient’s quality indicator are
gathered, standardized, and combined into a quality
index. This composite measure is a formative construct
as it is expected that the different quality indicators will
correlate [19]. In order to test for the robustness of the
results, scenario or probabilistic sensitivity analyses or
both are planned.
For the secondary endpoints, we will apply mostly mul-
tiple regressions using the differences in the quality
Table 1 Summary of critical values
PROM Sets Month 1 Month 3 Month 6 Critical developments*
EQ-5D-5L hip 0.37 0.64 0.74 Yes
HOOS-PS 53.00 36.30 27.70 Yes
EQ-5D-5L knee 0.36 0.51 0.70 Yes
KOOS-PS 51.60 43.60 33.60 Yes
PROMIS Depression 65.80 65.80 65.80 No
PROMIS Fatigue 69.00 69.00 69.00 No
Abbreviations: EQ-5D-5L EuroQoL 5-dimension 5-level, HOOS-PS Hip disability and Osteoarthritis Outcome Score-Physical Function Short-form, KOOS-PS Knee injury
and Osteoarthritis Outcome Score-Physical Function Short-form, PROM Patient-reported outcome measure, PROMIS Patient‐Reported Outcomes Measurement
Information System
* Alerts at critical development defined as worsening score compared with previous questionnaire
Kuklinski et al. Trials          (2020) 21:322 Page 7 of 10
indicator outcomes and improvements between the inter-
vention and control groups. Several subgroup-level analyses
for distinct and relevant patient cohorts will be performed.
Besides others, subgroups will cover age, sex, education,
mobilization, comorbidity, and type of prosthesis.
Data management
The collection, storage, and processing of personal data in
this study are carried out in accordance with the applic-
able data protection regulations of the federal states in
connection with the European General Data Protection
Regulation (GDPR) and take into account the specific pro-
visions of the German Social Code, Tenth Book (SGB X).
During the study, all data recorded electronically or in the
hospital will be stored at the respective hospital servers
and can be accessed or decrypted only by authorized users
in the hospital environment. Data will be transferred to a
secured personalized access SFTP-Server of the evaluating
institute. Every authorized user is assigned to a separate
area on the server where transport-encrypted (AES-256)
data can be stored and retrieved.
All transferred data will be completely pseudonymized.
Consequently, to match primary patient data to hospital
administrative data and insurance claims data, a pseudo-
nym will be created by the study’s software following
UUID (universally unique identifier) standard and is
added to the patient data. The pseudonym will be added
to the hospital administrative data and insurance claims
data. All other identification data will be deleted before
it is transferred to the researching institute. Pseudony-
mized data will be stored for two years at the research-
ing institute (Technical University Berlin, or TU Berlin)
and stored at study centers for 10 years after the study
completion to ensure further evaluation of study results.
This complies with the recommendation for good prac-
tice for secondary data analysis [20].
Study management
Study management is led by the project team at TU
Berlin. The overall project team consists of the person re-
sponsible for the study design, members from the two par-
ticipating German sickness funds, the technical provider,
and all study assistants. The team meets on a regular one-
month basis by teleconference to discuss the progress and
solve arising problems. Regular one-on-one calls are con-
ducted between the TU Berlin project team and study as-
sistants to ensure that enrollment is in line with the study
protocol. Additionally, on-site visits are planned every 3–
4months. During these sessions, study management will
monitor adherence to the study design.
Furthermore, intermediate reports with statistics on
recruitment and follow-up rates are sent to the study
management each month. Regular status updates are
sent to the study sponsor. Intermediate reports contain
only aggregated data without participant-specific data.
After 6 and 12 months, patient data sets will be extracted
from the software to check data quality and consistency.
Moreover, payouts to the hospitals are linked to patient
recruitment rates (based on their internally projected
yearly case volume) and follow-up completion rates.
Therefore, study assistants need to export statistics at
given points in time to receive full compensation. Owing
to the character of the study, no adverse effects are ex-
pected, but unfavorable developments will initiate an
intervention and be part of the study design.
Discussion
Recent studies have shown the value of PROMs in moni-
toring patients’ recovery paths in oncologic settings [12,
13] as well as their effectiveness in measuring patient-
relevant quality after TKR/THR [7, 8]. However, to the
best of our knowledge, no RCT has examined outcome
improvement and cost-effectiveness of monitoring and
intervening in case of critical recovery paths with the
help of PROMs.
Insights
Depending on a positive and cost-effective impact of the
intervention, a further aim is to evaluate the feasibility of
implementing regular and digitized PROM-based com-
munication into standard care. Furthermore, results
from this study can be leveraged to define and imple-
ment selective contracts between sickness funds and
health providers based on quality indicators [21]. The
setup phase of our study revealed several insights.
First, digitized PROMs can be a benefit but also a chal-
lenge to hospitals as well as patients. Unfortunately, the
collection of PROMs on paper has been not effective and
there have been low follow-up return rates and the burden
of additional documentation work for hospitals. Digitized
PROMs promise higher return rates and significantly
reduced documentation work. Nevertheless, hospital IT
departments need to be collaborative and personnel need
to be trained to familiarize patients with digital tools.
Second, structural changes are needed to enable seam-
less implementation of the study design. The effectiveness
of PROMs requires acceptance by physicians as well as
hospital management. It could be observed that a move
toward patient centeredness was generally perceived as
very positive by physicians and study assistants. Neverthe-
less, resources are required for personnel who familiarize
patients with PROMs and their relevance in the aftercare
and who compile the data. This relationship between
study assistant and patient is the central lever for data
quality and completeness. Moreover, effective communi-
cation channels between hospitals and outpatient physi-
cians and patients are key for the best possible recovery
pathway. Often, this communication is disrupted because
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of the boundaries between the siloed in- and outpatient
sector in the German health-care system.
Third, data privacy and security regulation were
challenging factors in the setup of the study. New data
security regulations complicate the communication
between hospitals, patients, and outpatient physicians.
A common nation-wide health data platform for col-
lecting data and for communicating results could be
an interesting idea for further discussion.
Lastly, in Germany, there is a diverse landscape of
hospitals, ranging from full-service providers to spe-
cialized hospitals and specialist outpatient clinics. The
diversity of the set of hospitals in the study sample
already indicates that a standardized “one size fits all”
process will not work. The collected insights in hind-
sight can be leveraged for further analysis to define
the degree of standardization in the approach.
Limitations
There are a number of limitations to the study at hand.
First, owing to data security regulations and complexity,
outpatient physicians are not formally part of the study.
Unfortunately, we can only advise but not oblige the
outpatient physicians to use the participants’ critical
PROM results in their further treatment plan. We try to
convince them of the study relevance by sending infor-
mation material, directing them to our study website,
and thorough conversation with the participant. Second,
patients without direct or indirect access to an e-mail
address cannot be included in the study. We hope to
minimize this effect by involving their relatives. Third,
there is no empirical evidence on critical PROM values
at specific points in time yet. We have tried to overcome
this limitation with the formation of an expert consor-
tium and a real data check. Nevertheless, the defined
critical values might be over- or underestimated, thus in-
cluding participants with non-critical recovery paths or
missing participants with critical recovery paths.
Fourth, participants in the intervention group might
have a learning curve when responding to the follow-
up questionnaires, deliberately avoiding interventions.
From our point of view, this effect is unlikely as the
participant does not profit from avoiding interven-
tions. Finally, differences between study centers in
personnel, organization, and infrastructure might in-
fluence the patient pathway during hospital stay des-
pite adherence to the study protocol.
Dissemination
The results of this study will be submitted for publi-
cation in relevant journals, presented in relevant con-
ferences, and used in the political discourse. Results
will play a role in conversations with the sickness
funds and the Federal Joint Committee for developing
German-wide implementation. Participating hospitals
will be included in the publications and have the
right for publication of their data. All results will be
on an aggregated basis and cannot be connected to
individual participants.
Trial status
The current protocol is version 1, dated January 15, 2019.
Recruitment of patients began, dependent on the study
center, between October 1 and January 1, 2020 and will
end around December 31, 2020. The trial was still open at
the time of study protocol submission. The study is ex-
pected to run until March 31, 2023.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-04252-y.
Additional file 1. Informed consent.
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